{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:39:58Z","timestamp":1791146398499,"version":"4.1.0"},"reference-count":97,"publisher":"Baishideng Publishing Group Inc.","issue":"28","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2009]]},"DOI":"10.3748\/wjg.15.3472","type":"journal-article","created":{"date-parts":[[2009,7,27]],"date-time":"2009-07-27T00:37:27Z","timestamp":1248655047000},"page":"3472","source":"Crossref","is-referenced-by-count":44,"title":["Targeting host factors: A novel rationale for the management of hepatitis C virus"],"prefix":"10.3748","volume":"15","author":[{"given":"Mahmoud Aboelneen","family":"Khattab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"ref1","unstructured":"World Health Organization. Hepatitis C. Fact sheet number 164. Available from: URL: <ext-link ext-link-type=\"uri\" xlink:href=\"www.who.int\/mediacentre\/factsheets\/fs164\/en\/\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\"> http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/<\/ext-link>."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Medhat A, Shehata M, Magder LS, Mikhail N, Abdel-Baki L, Nafeh M, Abdel-Hamid M, Strickland GT, Fix AD. Hepatitis c in a community in Upper Egypt: risk factors for infection. Am J Trop Med Hyg 2002;66:633-638.","DOI":"10.4269\/ajtmh.2002.66.633"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Habib M, Mohamed MK, Abdel-Aziz F, Magder LS, Abdel-Hamid M, Gamil F, Madkour S, Mikhail NN, Anwar W, Strickland GT. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. Hepatology 2001;33:248-253.","DOI":"10.1053\/jhep.2001.20797"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.","DOI":"10.1056\/NEJM200107053450107"},{"key":"ref5","unstructured":"NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002;19:1-46."},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Hnatyszyn HJ. Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antivir Ther 2005;10:1-11.","DOI":"10.1177\/135965350501000118"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. Hepatology 2006;43:S207-S220.","DOI":"10.1002\/hep.21064"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Gao B, Hong F, Radaeva S. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology 2004;39:880-890.","DOI":"10.1002\/hep.20139"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005;436:953-960.","DOI":"10.1038\/nature04080"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Aizaki H, Morikawa K, Fukasawa M, Hara H, Inoue Y, Tani H, Saito K, Nishijima M, Hanada K, Matsuura Y. Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection. J Virol 2008;82:5715-5724.","DOI":"10.1128\/JVI.02530-07"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Meuleman P, Hesselgesser J, Paulson M, Vanwolleghem T, Desombere I, Reiser H, Leroux-Roels G. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 2008;48:1761-1768.","DOI":"10.1002\/hep.22547"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Monazahian M, Kippenberger S, M&uuml;ller A, Seitz H, B&ouml;hme I, Grethe S, Thomssen R. Binding of human lipoproteins (low, very low, high density lipoproteins) to recombinant envelope proteins of hepatitis C virus. Med Microbiol Immunol 2000;188:177-184.","DOI":"10.1007\/s004300000032"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Thomssen R, Bonk S, Propfe C, Heermann KH, K&ouml;chel HG, Uy A. Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol 1992;181:293-300.","DOI":"10.1007\/BF00198849"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Thomssen R, Bonk S, Thiele A. Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins. Med Microbiol Immunol 1993;182:329-334.","DOI":"10.1007\/BF00191948"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Castet V, Moradpour D. A model for the study of hepatitis C virus entry. Hepatology 2003;38:771-774.","DOI":"10.1002\/hep.510380328"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Blanchard E, Belouzard S, Goueslain L, Wakita T, Dubuisson J, Wychowski C, Rouill&eacute; Y. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol 2006;80:6964-6972.","DOI":"10.1128\/JVI.00024-06"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Codran A, Royer C, Jaeck D, Bastien-Valle M, Baumert TF, Kieny MP, Pereira CA, Martin JP. Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis. J Gen Virol 2006;87:2583-2593.","DOI":"10.1099\/vir.0.81710-0"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G. Binding of hepatitis C virus to CD81. Science 1998;282:938-941.","DOI":"10.1126\/science.282.5390.938"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002;21:5017-5025.","DOI":"10.1093\/emboj\/cdf529"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999;96:12766-12771.","DOI":"10.1073\/pnas.96.22.12766"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, W&ouml;lk B, Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007;446:801-805.","DOI":"10.1038\/nature05654"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Catanese MT, Graziani R, von Hahn T, Moreau M, Huby T, Paonessa G, Santini C, Luzzago A, Rice CM, Cortese R. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol 2007;81:8063-8071.","DOI":"10.1128\/JVI.00193-07"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Kitadokoro K, Bordo D, Galli G, Petracca R, Falugi F, Abrignani S, Grandi G, Bolognesi M. CD81 extracellular domain 3D structure: insight into the tetraspanin superfamily structural motifs. EMBO J 2001;20:12-18.","DOI":"10.1093\/emboj\/20.1.12"},{"key":"ref24","unstructured":"Liu C, Coco D, Dong HJ, Eksioglu E, Zhu H, Ostrov D. ."},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Rhainds D, Brissette L. The role of scavenger receptor class B type I (SR-BI) in lipid trafficking. defining the rules for lipid traders. Int J Biochem Cell Biol 2004;36:39-77.","DOI":"10.1016\/S1357-2725(03)00173-0"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996;271:518-520.","DOI":"10.1126\/science.271.5248.518"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Nieland TJ, Ehrlich M, Krieger M, Kirchhausen T. Endocytosis is not required for the selective lipid uptake mediated by murine SR-BI. Biochim Biophys Acta 2005;1734:44-51.","DOI":"10.1016\/j.bbalip.2005.02.007"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, Pawlotsky JM, Lavillette D, Cosset FL. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 2005;79:8217-8229.","DOI":"10.1128\/JVI.79.13.8217-8229.2005"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Maillard P, Huby T, Andr&eacute;o U, Moreau M, Chapman J, Budkowska A. The interaction of natural hepatitis C virus with human scavenger receptor SR-BI\/Cla1 is mediated by ApoB-containing lipoproteins. FASEB J 2006;20:735-737.","DOI":"10.1096\/fj.05-4728fje"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)\/LDL analyzed in iodixanol density gradients. J Virol 2006;80:2418-2428.","DOI":"10.1128\/JVI.80.5.2418-2428.2006"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, Scarselli E, Cortese R, Nicosia A, Cosset FL. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 2003;278:41624-41630.","DOI":"10.1074\/jbc.M305289200"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Chazal N, Gerlier D. Virus entry, assembly, budding, and membrane rafts. Microbiol Mol Biol Rev 2003;67:226-237, table of contents.","DOI":"10.1128\/MMBR.67.2.226-237.2003"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Rawat SS, Viard M, Gallo SA, Rein A, Blumenthal R, Puri A. Modulation of entry of enveloped viruses by cholesterol and sphingolipids (Review). Mol Membr Biol 2003;20:243-254.","DOI":"10.1080\/0968768031000104944"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Barth H, Schnober EK, Neumann-Haefelin C, Thumann C, Zeisel MB, Diepolder HM, Hu Z, Liang TJ, Blum HE, Thimme R. Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells. J Virol 2008;82:3466-3479.","DOI":"10.1128\/JVI.02478-07"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, Mangeot PE, Keck Z, Foung S, Vu-Dac N, Dubuisson J. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem 2006;281:18285-18295.","DOI":"10.1074\/jbc.M602706200"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Voisset C, Op de Beeck A, Horellou P, Dreux M, Gustot T, Duverlie G, Cosset FL, Vu-Dac N, Dubuisson J. High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry. J Gen Virol 2006;87:2577-2581.","DOI":"10.1099\/vir.0.81932-0"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Dustin LB, Rice CM. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol 2007;25:71-99.","DOI":"10.1146\/annurev.immunol.25.022106.141602"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Dreux M, Boson B, Ricard-Blum S, Molle J, Lavillette D, Bartosch B, P&eacute;cheur EI, Cosset FL. The exchangeable apolipoprotein ApoC-I promotes membrane fusion of hepatitis C virus. J Biol Chem 2007;282:32357-32369.","DOI":"10.1074\/jbc.M705358200"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Grove J, Huby T, Stamataki Z, Vanwolleghem T, Meuleman P, Farquhar M, Schwarz A, Moreau M, Owen JS, Leroux-Roels G. Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol 2007;81:3162-3169.","DOI":"10.1128\/JVI.02356-06"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Kapadia SB, Barth H, Baumert T, McKeating JA, Chisari FV. Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol 2007;81:374-383.","DOI":"10.1128\/JVI.01134-06"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Zeisel MB, Fafi-Kremer S, Fofana I, Barth H, Stoll-Keller F, Doffoel M, Baumert TF. Neutralizing antibodies in hepatitis C virus infection. World J Gastroenterol 2007;13:4824-4830.","DOI":"10.3748\/wjg.v13.i36.4824"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Andr&eacute; P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, Pol S, Br&eacute;chot C, Paranhos-Baccal&agrave; G, Lotteau V. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002;76:6919-6928.","DOI":"10.1128\/JVI.76.14.6919-6928.2002"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Andr&eacute;o U, Maillard P, Kalinina O, Walic M, Meurs E, Martinot M, Marcellin P, Budkowska A. Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection. Cell Microbiol 2007;9:2445-2456.","DOI":"10.1111\/j.1462-5822.2007.00972.x"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Jolly C, Kashefi K, Hollinshead M, Sattentau QJ. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med 2004;199:283-293.","DOI":"10.1084\/jem.20030648"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Bangham CR. The immune control and cell-to-cell spread of human T-lymphotropic virus type 1. J Gen Virol 2003;84:3177-3189.","DOI":"10.1099\/vir.0.19334-0"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Vassalli JD, Lombardi T, Wohlwend A, Montesano R, Orci L. Direct cell-to-cell transmission of vesicular stomatitis virus. J Cell Sci 1986;85:125-131.","DOI":"10.1242\/jcs.85.1.125"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Timpe JM, Stamataki Z, Jennings A, Hu K, Farquhar MJ, Harris HJ, Schwarz A, Desombere I, Roels GL, Balfe P. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 2008;47:17-24.","DOI":"10.1002\/hep.21959"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Witteveldt J, Evans MJ, Bitzegeio J, Koutsoudakis G, Owsianka AM, Angus AG, Keck ZY, Foung SK, Pietschmann T, Rice CM. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol 2009;90:48-58.","DOI":"10.1099\/vir.0.006700-0"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Koike K. Hepatitis C as a metabolic disease: Implication for the pathogenesis of NASH. Hepatol Res 2005;33:145-150.","DOI":"10.1016\/j.hepres.2005.09.023"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"J&aacute;rmay K, Kar&aacute;csony G, Nagy A, Schaff Z. Changes in lipid metabolism in chronic hepatitis C. World J Gastroenterol 2005;11:6422-6428.","DOI":"10.3748\/wjg.v11.i41.6422"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Bahtiyar G, Shin JJ, Aytaman A, Sowers JR, McFarlane SI. Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights. Curr Diab Rep 2004;4:194-198.","DOI":"10.1007\/s11892-004-0023-7"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Schiefke I, Fach A, Wiedmann M, Aretin AV, Schenker E, Borte G, Wiese M, Moessner J. Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol 2005;11:1843-1847.","DOI":"10.3748\/wjg.v11.i12.1843"},{"key":"ref53","unstructured":"Nanda KS, Ryan EJ, Murray BF, Brady JJ, McKenna MJ, Nolan N, O'Farrelly C, Hegarty JE. The effect of chronic hepatitis C virus infection on bone disease in postmenopausal women. Clin Gastroenterol Hepatol 2009;11:Jan 24. [Epub ahead of print]."},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Torres DM, Harrison SA. HCV replication and statin pleotropism: an adjuvant treatment panacea? Am J Gastroenterol 2008;103:1390-1392.","DOI":"10.1111\/j.1572-0241.2008.01881.x"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Ye J, Wang C, Sumpter R Jr, Brown MS, Goldstein JL, Gale M Jr. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci USA 2003;100:15865-15870.","DOI":"10.1073\/pnas.2237238100"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 2005;102:2561-2566.","DOI":"10.1073\/pnas.0409834102"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 2006;44:117-125.","DOI":"10.1002\/hep.21232"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Bader T, Fazili J, Madhoun M, Aston C, Hughes D, Rizvi S, Seres K, Hasan M. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 2008;103:1383-1389.","DOI":"10.1111\/j.1572-0241.2008.01876.x"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M Jr, Ye J. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci USA 2007;104:5848-5853.","DOI":"10.1073\/pnas.0700760104"},{"key":"ref60","unstructured":"Burnett JR. Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia. Curr Opin Mol Ther 2006;8:461-467."},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, Millar JS, Ikewaki K, Siegelman ES, Gregg RE. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007;356:148-156.","DOI":"10.1056\/NEJMoa061189"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Chandler CE, Wilder DE, Pettini JL, Savoy YE, Petras SF, Chang G, Vincent J, Harwood HJ Jr. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res 2003;44:1887-1901.","DOI":"10.1194\/jlr.M300094-JLR200"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, Shimotohno K. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005;19:111-122.","DOI":"10.1016\/j.molcel.2005.05.014"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Flisiak R, Horban A, Gallay P, Bobardt M, Selvarajah S, Wiercinska-Drapalo A, Siwak E, Cielniak I, Higersberger J, Kierkus J. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 2008;47:817-826.","DOI":"10.1002\/hep.22131"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Romero-G&oacute;mez M. Insulin resistance and hepatitis C. World J Gastroenterol 2006;12:7075-7080.","DOI":"10.3748\/wjg.v12.i44.7075"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003;39:1049-1055.","DOI":"10.1016\/S0168-8278(03)00456-2"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Romero-G&oacute;mez M, Del Mar Viloria M, Andrade RJ, Salmer&oacute;n J, Diago M, Fern&aacute;ndez-Rodr&iacute;guez CM, Corpas R, Cruz M, Grande L, V&aacute;zquez L. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-641.","DOI":"10.1053\/j.gastro.2004.12.049"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Mbow ML, Sarisky RT. What is disrupting IFN-alpha's antiviral activity? Trends Biotechnol 2004;22:395-399.","DOI":"10.1016\/j.tibtech.2004.06.002"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, Taniguchi E, Kumemura H, Hanada S, Maeyama M. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004;165:1499-1508.","DOI":"10.1016\/S0002-9440(10)63408-6"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Pazienza V, Cl&eacute;ment S, Pugnale P, Conzelman S, Foti M, Mangia A, Negro F. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007;45:1164-1171.","DOI":"10.1002\/hep.21634"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Knobler H, Zhornicky T, Sandler A, Haran N, Ashur Y, Schattner A. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol 2003;98:2751-2756.","DOI":"10.1111\/j.1572-0241.2003.08728.x"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, Moriya K, Koike K. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004;126:840-848.","DOI":"10.1053\/j.gastro.2003.11.056"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, Powell EE. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006;55:529-535.","DOI":"10.1136\/gut.2005.069674"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Bernsmeier C, Duong FH, Christen V, Pugnale P, Negro F, Terracciano L, Heim MH. Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C. J Hepatol 2008;49:429-440.","DOI":"10.1016\/j.jhep.2008.04.007"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006;21:1366-1371.","DOI":"10.1111\/j.1440-1746.2006.04559.x"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Romero-Gomez M, Diago M, Andrade RJ, Calleja JL, Salmeron J, Fernandez-Rodriguez CM, Sol\u0155 R, Herrerias JM, Garcia-Samaniego J, Moreno-Otero R. Metformin with peginterferon alfa-2a and ribavirin in the treatment of na&iuml;ve genotype 1 chronic hepatitis C patients with insulin resistance (TRIC-1): final results of a randomized and double-blinded trial. Hepatology 2008;48:380A.","DOI":"10.1016\/S0168-8278(08)61003-X"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Nagashima K, Lopez C, Donovan D, Ngai C, Fontanez N, Bensadoun A, Fruchart-Najib J, Holleran S, Cohn JS, Ramakrishnan R. Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 2005;115:1323-1332.","DOI":"10.1172\/JCI200523219"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Negro F. Peroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistance. PPAR Res 2009;2009:483485.","DOI":"10.1155\/2009\/483485"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Frederiksen KS, Wulf EM, Wassermann K, Sauerberg P, Fleckner J. Identification of hepatic transcriptional changes in insulin-resistant rats treated with peroxisome proliferator activated receptor-alpha agonists. J Mol Endocrinol 2003;30:317-329.","DOI":"10.1677\/jme.0.0300317"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Jay MA, Ren J. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Curr Diabetes Rev 2007;3:33-39.","DOI":"10.2174\/157339907779802067"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Li X, Hansen PA, Xi L, Chandraratna RA, Burant CF. Distinct mechanisms of glucose lowering by specific agonists for peroxisomal proliferator activated receptor gamma and retinoic acid X receptors. J Biol Chem 2005;280:38317-38327.","DOI":"10.1074\/jbc.M505853200"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci USA 2003;100:6712-6717.","DOI":"10.1073\/pnas.1031789100"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Henson P. Suppression of macrophage inflammatory responses by PPARs. Proc Natl Acad Sci USA 2003;100:6295-6296.","DOI":"10.1073\/pnas.1232410100"},{"key":"ref84","unstructured":"Conjeevaram H, Burant CF, McKenna , Harsh D, Kang H, Das AK, Everett L, White D, Lok ASF. A randomized, double-blind, placebo-controlled study of PPAR-gamma agonist pioglitazone given in combination with peginterferon and ribavirin in patients with genotype-1 chronic hepatitis C. Hepatology 2008;48:384A."},{"key":"ref85","unstructured":"Elgouhari HM, Cesario KB, Lopez R, Zein NN. Pioglitazone improves early virologic kinetic response to PEG IFN\/RBV combination therapy in hepatitis C genotype 1 na&iuml;ve pts. Hepatology 2008;48:383A."},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"de Gottardi A, Pazienza V, Pugnale P, Bruttin F, Rubbia-Brandt L, Juge-Aubry CE, Meier CA, Hadengue A, Negro F. Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Aliment Pharmacol Ther 2006;23:107-114.","DOI":"10.1111\/j.1365-2036.2006.02729.x"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Takada N, Sanda T, Okamoto H, Yang JP, Asamitsu K, Sarol L, Kimura G, Uranishi H, Tetsuka T, Okamoto T. RelA-associated inhibitor blocks transcription of human immunodeficiency virus type 1 by inhibiting NF-kappaB and Sp1 actions. J Virol 2002;76:8019-8030.","DOI":"10.1128\/JVI.76.16.8019-8030.2002"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Fujita N, Kaito M, Kai M, Sugimoto R, Tanaka H, Horiike S, Konishi M, Iwasa M, Watanabe S, Adachi Y. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin. J Viral Hepat 2006;13:441-448.","DOI":"10.1111\/j.1365-2893.2005.00718.x"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Chang KO, George DW. Bile acids promote the expression of hepatitis C virus in replicon-harboring cells. J Virol 2007;81:9633-9640.","DOI":"10.1128\/JVI.00795-07"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Podevin P, Rosmorduc O, Conti F, Calmus Y, Meier PJ, Poupon R. Bile acids modulate the interferon signalling pathway. Hepatology 1999;29:1840-1847.","DOI":"10.1002\/hep.510290617"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Li X, Huang J, Yi P, Bambara RA, Hilf R, Muyan M. Single-chain estrogen receptors (ERs) reveal that the ERalpha\/beta heterodimer emulates functions of the ERalpha dimer in genomic estrogen signaling pathways. Mol Cell Biol 2004;24:7681-7694.","DOI":"10.1128\/MCB.24.17.7681-7694.2004"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Watashi K, Inoue D, Hijikata M, Goto K, Aly HH, Shimotohno K. Anti-hepatitis C virus activity of tamoxifen reveals the functional association of estrogen receptor with viral RNA polymerase NS5B. J Biol Chem 2007;282:32765-73272.","DOI":"10.1074\/jbc.M704418200"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Anderson VR, Curran MP. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs 2007;67:1947-1967.","DOI":"10.2165\/00003495-200767130-00015"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, Ayers MS, Rossignol JF. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 2008;77:56-63.","DOI":"10.1016\/j.antiviral.2007.08.005"},{"key":"ref95","unstructured":"Elazar M, Liu M, McKenna S, Liu P, Gehrig EA, Elfert A, Puglisi J, Rossignol JF, Glenn JS. Nitazoxanide (NTZ) is an inducer of eIF2a and PKR phosphorylation [abstract]. Hepatology 2008;48:1151A."},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Korba BE, Elazar M, Lui P, Rossignol JF, Glenn JS. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother 2008;52:4069-4071.","DOI":"10.1128\/AAC.00078-08"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 2009;136:856-862.","DOI":"10.1053\/j.gastro.2008.11.037"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v15\/i28\/3472.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T04:19:57Z","timestamp":1685074797000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v15\/i28\/3472.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":97,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.15.3472","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2009]]}}}